A series of detailed statistical and methodological critiques of landmark cardiology trials. Each review examines study design, statistical analysis plans, interim analyses, ethical considerations, and clinical implications — written to be accessible to cardiologists without a specialist statistics background.
| Trial | Year | Lead Author | Summary | Review |
|---|---|---|---|---|
| CAPRICORN | 2001 | Dargie et al. | Randomised, double-blind carvedilol vs placebo in LV dysfunction post-MI; mid-trial endpoint split raised multiplicity concerns. | Read Review → |
| SPRINT | 2015 | Wright et al. | Landmark RCT of SBP targets; intensive control reduced events but early stopping raised interpretation issues. | Read Review → |